View in EDS HTML Full Text PDF Full Text

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.

Saved in:
Bibliographic Details
Title: Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
Authors: Pensato, Umberto (AUTHOR), Baraldi, Carlo (AUTHOR), Favoni, Valentina (AUTHOR), Cainazzo, Maria Michela (AUTHOR), Torelli, Paola (AUTHOR), Querzani, Pietro (AUTHOR), Pascazio, Alessia (AUTHOR), Mascarella, Davide (AUTHOR), Matteo, Eleonora (AUTHOR), Quintana, Simone (AUTHOR), Asioli, Gian Maria (AUTHOR), Cortelli, Pietro (AUTHOR), Pierangeli, Giulia (AUTHOR), Guerzoni, Simona (AUTHOR), Cevoli, Sabina (AUTHOR)
Source: Neurological Sciences. Feb2022, Vol. 43 Issue 2, p1273-1280. 8p. 2 Charts, 4 Graphs.
Abstract: Objective: To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache. Methods: In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. Study inclusion was limited to patients who previously failed onabotulinumtoxinA in addition to at least three other pharmacological commonly used migraine preventive medication classes. Results: Of 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved ≥ 50% and ≥ 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 ± 35.3 to 16.8 ± 13.9 (p < 0.001), while monthly headache days decreased from 25.4 ± 5.4 to 14.1 ± 8.6 (p < 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed. Conclusions: Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 154884200
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pensato%2C+Umberto%22&quot;&gt;Pensato, Umberto&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Baraldi%2C+Carlo%22&quot;&gt;Baraldi, Carlo&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Favoni%2C+Valentina%22&quot;&gt;Favoni, Valentina&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cainazzo%2C+Maria+Michela%22&quot;&gt;Cainazzo, Maria Michela&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Torelli%2C+Paola%22&quot;&gt;Torelli, Paola&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Querzani%2C+Pietro%22&quot;&gt;Querzani, Pietro&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pascazio%2C+Alessia%22&quot;&gt;Pascazio, Alessia&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mascarella%2C+Davide%22&quot;&gt;Mascarella, Davide&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Matteo%2C+Eleonora%22&quot;&gt;Matteo, Eleonora&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Quintana%2C+Simone%22&quot;&gt;Quintana, Simone&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Asioli%2C+Gian+Maria%22&quot;&gt;Asioli, Gian Maria&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cortelli%2C+Pietro%22&quot;&gt;Cortelli, Pietro&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pierangeli%2C+Giulia%22&quot;&gt;Pierangeli, Giulia&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Guerzoni%2C+Simona%22&quot;&gt;Guerzoni, Simona&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cevoli%2C+Sabina%22&quot;&gt;Cevoli, Sabina&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Neurological+Sciences%22&quot;&gt;Neurological Sciences&lt;/searchLink&gt;. Feb2022, Vol. 43 Issue 2, p1273-1280. 8p. 2 Charts, 4 Graphs.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache. Methods: In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. Study inclusion was limited to patients who previously failed onabotulinumtoxinA in addition to at least three other pharmacological commonly used migraine preventive medication classes. Results: Of 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved ≥ 50% and ≥ 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 &#177; 35.3 to 16.8 &#177; 13.9 (p &lt; 0.001), while monthly headache days decreased from 25.4 &#177; 5.4 to 14.1 &#177; 8.6 (p &lt; 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed. Conclusions: Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=154884200
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-021-05426-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 1273
    Titles:
      – TitleFull: Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pensato, Umberto
      – PersonEntity:
          Name:
            NameFull: Baraldi, Carlo
      – PersonEntity:
          Name:
            NameFull: Favoni, Valentina
      – PersonEntity:
          Name:
            NameFull: Cainazzo, Maria Michela
      – PersonEntity:
          Name:
            NameFull: Torelli, Paola
      – PersonEntity:
          Name:
            NameFull: Querzani, Pietro
      – PersonEntity:
          Name:
            NameFull: Pascazio, Alessia
      – PersonEntity:
          Name:
            NameFull: Mascarella, Davide
      – PersonEntity:
          Name:
            NameFull: Matteo, Eleonora
      – PersonEntity:
          Name:
            NameFull: Quintana, Simone
      – PersonEntity:
          Name:
            NameFull: Asioli, Gian Maria
      – PersonEntity:
          Name:
            NameFull: Cortelli, Pietro
      – PersonEntity:
          Name:
            NameFull: Pierangeli, Giulia
      – PersonEntity:
          Name:
            NameFull: Guerzoni, Simona
      – PersonEntity:
          Name:
            NameFull: Cevoli, Sabina
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1